TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~3.1.1 IgM paraprotein identified on serum immunofixation electrophoresis OR light chain-restricted CD20+ lymphoplasmacytic population on biopsy of bone marrow or lymph node (identified by H\&E/immunohistochemistry or flow cytometry) OR positive myeloid differentiation primary response gene 88 (MYD88-L265P) OR CXCR4WHIM mutation (CXCR4 mutation - warts, hypogammaglobulinemia, infections, myelokathexis) on submitted samples~3.1.2 Biopsy-proven relapsed or refractory AL amyloidosis~3.1.3 Age ≥ 18 years~3.1.4 Eastern Cooperative Oncology Group (ECOG) performance status \<2 (see Appendix A.)~3.1.5 Difference between serum free light chains (FLC) of \>30 mg/L or quantifiable IgM paraprotein \>0.5 g/L~3.1.6 Participants must have normal organ and marrow function as defined below:~* Absolute neutrophil count \> 1,000/mm3~* Platelets \> 50,000/mm3~3.1.7 Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~3.2.1 Previous treatment with idelalisib~3.2.2 Glomerular filtration rate (GFR) \<15 ml/min~3.2.3 Cardiac biomarker Stage III disease as determined by B-type natriuretic peptide (BNP) \>100 pg/mL and Troponin-I \>0.1 ng/mL (Girnius 2014)~3.2.4 alanine-aminotransferase (ALT)/aspartate aminotransferase (AST) values \>2.5x upper limit of normal, Bilirubin \>1.5 upper limit of normal (ULN)~3.2.5 Central nervous system (CNS) malignancy or other active malignancy~3.2.6 Lactating or pregnant women~3.2.7 Exposure to another investigational drug within 4 weeks prior to start of study treatment~3.2.8 Ongoing alcohol or drug addiction as determined by investigator~3.2.9 Amyloid-directed therapy within the past 28 days~3.2.10 History of Human Immunodeficiency Virus (HIV), active Hepatitis B Virus (HBV) (assessed by positive Hepatitis B polymerase chain reaction assay (PCR) or Hepatitis B Surface Antigen), and/or Hepatitis C Virus (HCV) infection~3.2.11 t(11,14) translocation identified on bone marrow cytogenetics or by Fluorescence in situ hybridization (FISH)~3.2.12 Known lytic bone lesions~3.2.13 Positive cytomegaly virus (CMV) Polymerase chain reaction (PCR)~3.2.14 Previously untreated AL amyloidosis (Newly diagnosed)~3.2.15 Unwilling or unable to comply with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Idelalisib (Type: EXPERIMENTAL): Idelalisib 100 mg twice daily with possible escalation after 3 months to 150 mg twice daily at investigator discretion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Alzheimer's disease~* On donepezil (Aricept)~* Caregiver who cares for the patient at least 5 days per week~Exclusion Criteria:~* Unstable medical illnesses or significant hepatic or renal disease~* Other primary psychiatric or neurological disorders

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dimebon (Type: EXPERIMENTAL): 20 mg by mouth 3 times a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cocamide DEA vs Permethrin for Head Lice

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients over the age of 4 who are found to have a head lice infection.~* Patients who give written informed consent or, if the patient is under 16 years of age, whose guardian gives written informed consent to participate in the study.~* Available for the duration of study i.e. 15 days.~Exclusion Criteria:~* Patients with a known sensitivity to pyrethroid, organophosphate, and/or carbamate insecticides, sensitivity to chrysanthemums and/or known sensitivity to paraben preservatives.~* Patients who have been treated with other head lice products within the last 4 weeks.~* Patients who have undergone a course of antibiotic treatment within the last 4 weeks.~* Patients who have any persistent skin disorder of the scalp (i.e. eczema, chronic dermatitis, psoriasis).~* Patients with asthma~* Patients whose hair has been bleached, colour treated or permed within the last 4 weeks.~* Pregnant or nursing mothers.~* Patients who have participated in another clinical trial within 1 month prior to entry to this study.~* Patients who have already participated in this clinical trial.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 10% Cocamide diethanolamine (Type: EXPERIMENTAL): 10% Cocamide DEA aqueous lotion is applied directly to dry hair on a single occasion and is washed off with shampoo after 60 minutes.
- 1% permethrin creme rinse (Type: ACTIVE_COMPARATOR): 1% permethrin creme rinse is applied to shampooed and towel dried hair on a single occasion and left in situ for 10 minutes, then rinsed off with clean water.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: H-29 DELTA Multihole TT Study.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects who underwent a Total Hip Arthroplasty with Delta Multihole TT acetabular cup, as per indications for use, in 2019 onwards~* Age ≥ 18 years old~* Subjects who have signed the written informed consent approved by the reference Ethics Committee (EC)~* Subjects able to comply with the protocol and to perform all scheduled follow-up visits~Exclusion Criteria:~* Male or female subjects who underwent a Total Hip Arthroplasty with Delta Multihole TT acetabular cup, but showed any of the contraindications reported in the Instruction for Use~* Age \< 18 years old~* Any clinically significant pathology based on clinical history that the Investigator feels may affect the study evaluation including, but not limited to:~  1. significant neurological or musculoskeletal disorders or disease that may adversely affect gait and compromise functional recovery.~ 2. neuromuscular or neurosensory deficit which would limit the ability to assess the performance of the device.~ 3. known metabolic disorders leading to progressive bone deterioration.~* Hip replacement on the contralateral side performed within less than one year.~* Female subjects who are pregnant, nursing or planning a pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HydroCoil Cerebral Aneurysm Treatment Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient presenting with a ruptured or un-ruptured cerebral aneurysm appropriate for endovascular treatment as determined by the neurovascular team (neurosurgeon/neurointerventionalist)~2. The neurointerventionalist believes that the aneurysm can be safely treated with either Cerecyte or Hydrogel.~3. Patients between (and including) 21 and 90 years of age.~4. Patient HUNT AND HESS Grade 0-3.~5. Patient has given fully informed consent to endovascular coiling procedure. If patient cannot consent for themselves, appropriate written consent has been sought from their next of kin, or from appropriate power of attorney.~6. Aneurysm 5-20mm in maximum diameter.~7. Patient is willing and able to return for clinical evaluation and follow-up imaging evaluation (angiography or MRA) at both 6-months and 12-18 months after endovascular treatment.~8. The patient has not been previously randomized into this or another related ongoing trial.~9. The aneurysm has not previously been treated (by coiling or clipping).~Exclusion Criteria:~1. Patient has more than one aneurysm requiring treatment in the current treatment session If a patient has multiple aneurysms, but only one will be treated at the time of enrollment, they are eligible for the trial. (Additional aneurysms may be treated at a later date, and may be treated with any coil type that the operator chooses).~2. Target aneurysm has had previous coil treatment or surgically clipped.~3. Patient has an H\&H score of 4 or 5 after subarachnoid hemorrhage (SAH).~4. Inability to obtain informed consent.~5. Medical or surgical co-morbidity such that the patient's life expectancy is less than 1 year.~   -

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- MicroVention Hydrogel Coils (Type: OTHER): FDA approved and in common use for cerebral aneurysm treatment.
- Non-hydrogel coils (Type: ACTIVE_COMPARATOR): Cerecyte or bare platinum coils (FDA approved and in common use for treatment of cerebral aneurysm).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women greater than or equal to 18 years of age;~* A mean baseline platelet count between:~  * 50 × 10\^9/L and \<100 × 10\^9/L for non-chronic liver disease participants~ * 50 × 10\^9/L and \<75 × 10\^9/L for participants with chronic liver disease;~* Participant is scheduled to undergo operations to critical sites (eg, eye surgery, neurosurgery) or operations with a high risk of bleeding (eg, major abdominal surgery), or, in the opinion of the Investigator, would otherwise require a pre-operative platelet transfusion to prevent bleeding~Exclusion Criteria:~* Participant with a history of arterial or venous thrombosis within 6 months of baseline;~* Participant with known portal vein blood flow velocity rate \<10 cm/second or previous portal vein thrombosis within 6 months of baseline;~* Participant plans to have a platelet transfusion or plans to receive blood products containing platelets within 7 days of the Baseline Visit;~* Use of erythropoietin-stimulating agents;~* Participant has a known medical history of genetic prothrombotic syndromes; or~* Participant has abnormal hemoglobin levels or prothrombin time/international normalized ratio

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Avatrombopag 60 mg (Type: EXPERIMENTAL): Open-label: oral avatrombopag

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Duloxetine on Pathological Worry in Patients With Generalized Anxiety Disorder: A fMRI Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV criteria of generalized anxiety disorders with moderate degree~* Participants above 18 years old~Exclusion Criteria:~* Major depression~* Panic disorder~* Obsessive-compulsive disorder~* Post-traumatic disorder~* Eating disorders~* Psychotic disorders; and~* Alcohol or other substance use disorders~* Neurological disease~* Cardio-vascular disease~* Respiratory disease~* Head trauma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Revofit™ System Evaluation on Residual Limb Pain in Amputee Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 years old and above~* Above knee or below knee amputation (irrespective of etiology and time from amputation)~* Residual limb pain~* Prosthetic with classic fitting~* Fluctuations of residual limb requiring prosthetic adaptation (stump cotton sock, wedgning fitting ...)~* Recipients or registered with a social security scheme~* Informed consent form signed beforehand~Exclusion Criteria:~* Patient with peripheral neuropathies contraindicating the use of Revofit system~* Pregnant woman, nursing mother or parturiant~* Patient in detention by judicial or administrative decision~* Patient undergoing psychiatric compulsory care~* Patient in a health or social institution for purposes other than research~* Legally protected person~* Patient unable to express their consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adjustable socket (Type: EXPERIMENTAL): First week of the study is with adjustable socket
- Classical socket (Type: EXPERIMENTAL): First week of the study is with classical socket

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Safety and Efficacy of Dexmedetomidine and Propofol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is 3 - 11 years~* Patient is scheduled for MRI at Children's Hospital Boston.~* Patient meets criteria to receive either dexmedetomidine or propofol sedation~* Patient's guardian provides written consent~Exclusion Criteria:~* Patient does not meet established sedation criteria~* Patient has history of allergy, intolerance, or reaction to dexmedetomidine or propofol or hypersensitivity~* Patient has current, repaired, or risk for Moya-Moya disease~* Patient has had a stroke within the past six months~* Patient has uncontrolled hypertension~* Patient currently uses beta antagonist, alpha 2 agonist or calcium blocker~* Known soy, Lecithin, or egg allergy

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine Group (Type: ACTIVE_COMPARATOR): Dexmedetomidine given as 2mcg/kg bolus over 10 minutes followed by 1.5mcg/kg/hr infusion for duration of scan. The bolus may be repeated up to 2 times at any time during the sedation in the event that adequate sedation conditions (minimum Ramsay Sedation Score of 4) are not achieved. In the event that dexmedetomidine is unable to achieve motionless conditions, after a total of 3 boluses, 0.5 mg/kg IV pentobarbital may be administered at q1 minute intervals up to a maximum of 2 mg/kg, per established protocol.
- Propofol Group (Type: ACTIVE_COMPARATOR): Propofol bolus at an initial dose of 1 mg/kg over 1 minute then up to two additional 1 mg/kg boluses may be administered (total 3 mg/kg) - each over a one (1) minute interval, waiting 30 seconds after completion of each bolus to reassess sedation level. Once a minimum Ramsey Sedation Score 4 is achieved, an infusion at 125 mcg/kg/min is initiated. It may be titrated to 300 mcg/kg/min. If there is movement or awakening the patient may be rebolused with no more than 2 doses of Propofol at 1 mg/kg over 1 minute, in the same dosing manner as described above, waiting 30 seconds between doses. If adequate sedation is not achieved, 0.5 mg/kg IV pentobarbital may be administered at q1 minute intervals up to a maximum of 2 mg/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Embryo Selection by Time Lapse Monitoring for Single Embryo Transfer (SET)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \< 36 yrs~* baseline FSH \<10 IU/l~* regular 25-35 day cycles~* less than 2 previous failed IVF cycles~* intact uterus~* an indication for IVF~* BMI \<18- \<30 kg/m2~* acceptance of single embryo transfer~Exclusion Criteria:~* PCOS~* Sperm obtained by surgical extraction~* chromosome abnormality~* Presence of hydrosalpinx~* stage III/IV endometriosis~* Less than 3 good quality day 3 embryos~* only one good quality day 5 embryos~* lack of consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 36 Years
- Healthy Volunteers: t

Study Arms:
- time-lapse morphokinetic evaluation (Type: EXPERIMENTAL): Embryo selection for transfer based on a combind score made up of scores for kinetic parameters and standard morphology as seen on time-lapse: upon fertilization embryos in a petri dish that allows individual assessment (Primo Vision Dish) are placed onto an automated time-lapse equipment in an incubator. The time-lapse equipment performs imaging in 10 minutes intervals. The software is presenting the up-to-date images and allows the operator to assess the time-lapse movie of the developmental history of the embryos to perform annotations and apply evaluation/selection algorithm. This morpho-kinetic TL algorithm (made up of standard moprhology as seen on time lapse and kinetci scores) is used for embryo selection, which actually describes the intervention.
- standard embryo monitoring (Type: NO_INTERVENTION): Upon fertilization embryos are observed once on days 1-3-5 by the embryologist to check for development. The single embryo for transfer is selected based on actual morphology as seen under light microscope.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cutaneous and Systemic Reactions to Metal Implants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Age ≥18 years with a history of metal allergy who require joint repair (hip, knee and/or shoulder)~2. Able to undergo patch testing~Exclusion Criteria~1. Patients on oral immunosuppressant medications within 4 weeks of patch testing or topical corticosteroids to the back within 1 week of patch testing~2. Patients who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Metal Allergy Hx +, Metal Patch Test + (Type: OTHER): These are patients with a history of metal allergy who are patch test positive to metals (metal series, metal disc if available from manufacturer, bone cement components and topical antibiotics) prior to implantation of metal device.
- Metal Allergy Hx +, Metal Patch Test - (Type: OTHER): These are patients with a history of metal allergy who are patch test negative to metals (metal series, metal disc if available from manufacturer, bone cement components and topical antibiotics) prior to implantation of metal device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fluorescence-guided Resection in Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Caucasian female postmenopausal patients~* Patients with histologically confirmed primary palpable and nonpalpable breast cancer sized up to 5 cm (T1 - T2)~Exclusion Criteria:~* Suspicious lymphogenic metastases (cN1-3)~* Acute or chronic hepatic diseases~* Manifest renal diseases with renal dysfunction~* Relevant cardiac disease~* Preceding therapy of breast tumour under investigation~* Patients with multiple attempts of hook-wire placement in preparation of surgery~* Dementia or psychic condition that might interfere with the ability to understand the study and thus give a written informed consent~* Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding treatment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PD L 506 2nd dose (Type: ACTIVE_COMPARATOR): Different dosage
- PD L 506 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues